Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin
Research article published in Transfusion (2019)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder characterized by heparin-dependent antibodies that activate platelets (PLTs) via PLT FcγIIa receptors. "Autoimmune" HIT (aHIT) indicates a HIT subset where thrombocytopenia progresses or persists despite stopping heparin; aHIT sera activate PLTs strongly even in the absence of heparin (heparin-independent PLT-activating properties). Affected patients are at risk of severe complications, including dual macro- and microvascular thrombosis leading to venous limb gangrene. High-dose intravenous immunoglobulin (IVIG) offers an approach to interrupt heparin-independent PLT-activating effects of aHIT antibodies. CASE REPORT: A 78-year-old male who underwent cardiopulmonary bypass for aortic dissection developed aHIT, disseminated intravascular coagulation, and deep vein thrombosis; progression to venous limb gangrene occurred during partial thromboplastin time (PTT)-adjusted bivalirudin infusion (underdosing from "PTT confounding"). Thrombocytopenia recovered with high-dose IVIG, although the PLT count increase began only after the third dose of a 5-day IVIG regimen (0.4 g/kg/day × 5 days). We reviewed case reports and case series of IVIG for treating HIT, focusing on various IVIG dosing regimens used. RESULTS: Patient serum-induced PLT activation was inhibited in vitro by IVIG in a dose-dependent fashion; inhibition of PLT activation by IVIG was much more marked in the absence of heparin versus the presence of heparin (0.2 U/mL). Our literature review indicated 1 g/kg × 2 IVIG dosing as most common for treating HIT, usually associated with rapid PLT count recovery. CONCLUSION: Our clinical and laboratory observations support dose-dependent efficacy of IVIG for decreasing PLT activation and thus correcting thrombocytopenia in aHIT. Our case experience and literature review suggests dosing of 1 g/kg IVIG × 2 for patients with severe aHIT.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.
Warum dies für die Hirudotherapie relevant ist
Dieser Fallbericht mit begleitender Literaturübersicht beschreibt einen 78-jährigen Mann, der nach der Versorgung einer Aortendissektion eine autoimmune heparininduzierte Thrombozytopenie (aHIT) mit DIC, tiefer Venenthrombose und venöser Extremitätengangrän entwickelte; die Thrombozytopenie erholte sich unter hochdosiertem IVIG, In-vitro-Tests zeigten, dass IVIG die Thrombozytenaktivierung dosisabhängig hemmte (stärker ohne heparin), und die Autoren schlagen für schwere aHIT eine Dosierung von 1 g/kg × 2 vor. Es ist für die Hirudotherapie von Belang, weil die Gangrän des Patienten unter PTT-adjustiertem bivalirudin (einem direkten Thrombininhibitor derselben mechanistischen Klasse wie das aus Blutegeln gewonnene Antikoagulans hirudin) fortschritt, was sowohl den Reiz als auch die Dosierungsfallstricke der direkten Thrombininhibition veranschaulicht. Als einzelner Fall zuzüglich narrativer Übersicht sind die Befunde hypothesengenerierend und nicht definitiv, der In-vitro-IVIG-Effekt bedarf einer kontrollierten Bestätigung, und nichts hier betrifft die Blutegeltherapie selbst.
Zitation
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Arcinas et al. · Transfusion, 2019
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026